TPST-1120

TPST-1120 · Tempest Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TPST-1120, covering 2025-09-03 to 2025-09-03. Get the full timeline:

Most recent: Clinical Trial Update: A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy [Phase 3]

See pricing